CM
KRYS icon

Caption Management’s Krystal Biotech KRYS Stock Holding History

Caption Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.9M Buy
170,000
+64,700
+61% +$17.2M 0.26% 77
2025
Q4 		$26M Buy
105,300
+5,300
+5% +$1.12M 0.18% 125
2025
Q3 		$17.7M Sell
100,000
-20,000
-17% -$2.99M 0.14% 160
2025
Q2 		$16.5M Sell
120,000
-101,800
-46% -$15M 0.18% 110
2025
Q1 		$40M Buy
221,800
+143,300
+183% +$24.1M 0.38% 44
2024
Q4 		$12.3M Buy
78,500
+42,500
+118% +$7.54M 0.12% 149
2024
Q3 		$6.55M Sell
36,000
-42,700
-54% -$8.23M 0.1% 232
2024
Q2 		$14.5M Buy
78,700
+56,300
+251% +$9.45M 0.22% 98
2024
Q1 		$3.99M Sell
22,400
-17,600
-44% -$2.44M 0.06% 344
2023
Q4 		$4.96M Buy
40,000
+17,300
+76% +$1.92M 0.07% 341
2023
Q3 		$2.63M Buy
22,700
+2,700
+14% +$329K 0.04% 510
2023
Q2 		$2.35M Buy
+20,000
New +$2.04M 0.04% 455

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's KRYS Position: Q1 2025 in Review

Caption Management sold out of Krystal Biotech (KRYS) in Q1 2025, closing a stake of 22,339 shares — an estimated $3.76M sold.

Caption Management first reported a position in KRYS in Q4 2021 and held it in 3 quarters. The position peaked at $3.5M in Q4 2024. 299 funds tracked by Wall St. Rank hold KRYS as of Q1 2025.

  • Caption Management reported no remaining Krystal Biotech position as of Q1 2025 after selling out during the quarter.
  • Caption Management sold 22,339 Krystal Biotech shares in Q1 2025, an estimated $3.76M.
  • Caption Management first reported a position in Krystal Biotech in Q4 2021 and held it in 3 quarters.
  • Caption Management's Krystal Biotech position peaked at $3.5M in Q4 2024.
  • 299 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.